论文信息 - Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor - 字舞流文

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

A. Tolcher | K. Papadopoulos | B. Schwartz | G. Abbadessa | M. Saleh | W. Harb | F. Chai | M. Larmar